Cart
sales@molnova.com
HPK1-IN-7
CAS No. 2320462-65-3
HPK1-IN-7( —— )
Catalog No. M28709 CAS No. 2320462-65-3
HPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 167 | In Stock |
|
| 5MG | 167 | In Stock |
|
| 10MG | 276 | In Stock |
|
| 25MG | 449 | In Stock |
|
| 50MG | 603 | In Stock |
|
| 100MG | 830 | In Stock |
|
| 200MG | 1097 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHPK1-IN-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionHPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
-
DescriptionHPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
-
In Vitro——
-
In VivoAnimal Model:Mice (MC38 syngeneic tumor model)Dosage:100 mg/kg Administration:Oral; twice daily for 28 days Result:Enhanced the efficacy of anti-PD1 treatment, garnering a 100% cure rate vs a 20% cure rate with anti-PD1 alone.
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorEndothelin-1 receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2320462-65-3
-
Formula Weight458.478
-
Molecular FormulaC24H22N6O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (272.65 mM)
-
SMILESCC1(C)OC(=O)c2ccc(Nc3ncc(-c4nnco4)c(N[C@H](CO)c4ccccc4)n3)cc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kohno M, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 1992 Feb;70(2):241-7
molnova catalog
related products
-
NJK14047
NJK14047 is a novel potent, selective p38 MAPK inhibitor with IC50 of 27 nM against p38α.
-
dencichine
Dencichine is a neurotoxic agent. Dencichine is a haemostatic agent, the hemostatic effect relates to modulation of the coagulation system, platelet aggregation and fibrinolytic system.
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
